For example, vasoactive intestinal peptides are associated with itch intensity in AD, affect IFN-γ and IL-4 cytokine release, and increase the risk of IgE-mediated mycobacterial sensitization in AD, all of which suggest that neuropeptides may be used as better alternative biomarkers for AD [69]. This evidence concerns the gene VIP and Alzheimer disease.